US 11292815
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
granted A61KA61K38/00A61K38/005
Quick answer
US patent 11292815 (Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods) held by Apellis Pharmaceuticals, Inc. expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Apellis Pharmaceuticals, Inc.
- Grant date
- Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K38/00, A61K38/005, A61K38/10, A61K47/542